US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% SNDK $1,704.16 ▼-0.92%
FinancialContent

Articles published by ImmunoPrecise Antibodies Ltd.

< Previous 1 2 3 Next >
News headline image
ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
ImmunoPrecise Antibodies (IPA) to Present at Maxim Group’s 2025 Virtual Tech Conference
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
IPA’s LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
ImmunoPrecise Antibodies Announces Key Leadership Changes
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
IPA Announces Resignation of Chief Financial Officer
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
News headline image
ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
< Previous 1 2 3 Next >